Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiol Therapeutics (CRDL) Cash & Equivalents (2020 - 2026)

Cardiol Therapeutics filings provide 3 years of Cash & Equivalents readings, the most recent being $43.8 million for Q4 2022.

  • On a quarterly basis, Cash & Equivalents fell 34.18% to $43.8 million in Q4 2022 year-over-year; TTM through Dec 2022 was $43.8 million, a 34.18% decrease, with the full-year FY2022 number at $43.8 million, down 34.18% from a year prior.
  • Cash & Equivalents hit $43.8 million in Q4 2022 for Cardiol Therapeutics, down from $64.3 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $66.6 million in Q4 2021 to a low of $10.8 million in Q4 2020.
  • Median Cash & Equivalents over the past 3 years was $43.8 million (2022), compared with a mean of $39.0 million.
  • Biggest five-year swings in Cash & Equivalents: surged 518.7% in 2021 and later crashed 34.18% in 2022.
  • Cardiol Therapeutics' Cash & Equivalents stood at $10.8 million in 2020, then surged by 518.7% to $66.6 million in 2021, then crashed by 34.18% to $43.8 million in 2022.
  • The last three reported values for Cash & Equivalents were $43.8 million (Q4 2022), $64.3 million (Q3 2022), and $65.8 million (Q2 2022) per Business Quant data.